Helen M. Thackray - Jun 15, 2022 Form 4 Insider Report for ImmunoGen, Inc. (IMGN)

Role
Director
Signature
/s/ Renee Lentini, Attorney-in-Fact
Stock symbol
IMGN
Transactions as of
Jun 15, 2022
Transactions value $
$108,062
Form type
4
Date filed
6/17/2022, 04:09 PM
Previous filing
Apr 4, 2022
Next filing
Dec 19, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Deferred Share Unit Award $0 +10.9K +36.44% $0.00 40.9K Jun 15, 2022 Common Stock 10.9K $0.00 Direct F1, F2, F3
transaction IMGN Stock Option (right to buy) Award $108K +32.1K $3.37* 32.1K Jun 15, 2022 Common Stock 32.1K $3.37 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
F2 The deferred share units vest ratably over a one-year period in quarterly increments beginning on September 1, 2022, contingent upon the individual remaining a director as of each vesting date.
F3 The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
F4 The stock options vest ratably over a one-year period in quarterly increments beginning on September 1, 2022, contingent upon the individual remaining a director as of each vesting date.